Conference Coverage

Opioids appear safe for sickle cell pain


 

REPORTING FROM ASH 2018

– Inpatient deaths from opioid overdose in the U.S. population has risen dramatically in recent years, but this is essentially a “never event” among patients with sickle cell disease (SCD).

Dr. Oladimeji Akinola Akinboro

Dr. Oladimeji Akinola Akinboro

These findings come from an analysis of hospital discharge data in the National Inpatient Sample from 1998 to 2013. Oladimeji Akinola Akinboro, MBBS, who led the study, said the findings suggest that the current patterns of opioid use in SCD patients are safe and that opioids should not be withheld when they are appropriate.

From 1998 to 2013, the rate of inpatient deaths from opioid overdose in the United States rose 350% overall and approximately 8% annually. In contrast, deaths among SCD patients were flat, with a rate at or near zero throughout the same time period.

Over the 16-year period, there were just nine deaths reported among SCD patients because of opioids in the inpatient setting, Dr. Akinboro of Boston University Medical Center reported at the annual meeting of the American Society of Hematology.

While the reasons behind the difference were not explored in the study, Dr. Akinboro suggested that the sickle cell community has greater experience with opioids and that patients and physicians typically have long-standing clinical relationships that make mitigation of opioid misuse easier to manage.

Opioid-related hospitalizations, however, were comparable among the general U.S. population and SCD patients. And for both groups the rates remained relatively steady throughout the study period, with the exception of a drop among SCD patients in 2002, he noted.

The study also revealed age-related trends in hospitalizations overall. Hospitalizations among sickle cell patients were stable from 1998 to 2013. However, when the researchers broke the data down by age they found that adults aged 18-44 years had an increase in hospitalizations, with the steepest rise in patients aged 65 years and older.

In total, there were more than 1.7 million hospitalizations among SCD patients in the United States from 1998 to 2013. The rate declined by 9.9% each year from 1998 to 2002, then remained flat at around 27 per 100,000 persons from 2002 to 2013.

However, for adults aged 18-44 years, hospitalizations increased from 43 per 100,000 persons in 2002 to 71 per 100,000 persons in 2013 – an annual increase of 3.8%. Patients aged 65 years and older saw their rate of hospitalization increase from 2.7 to 5.4 per 100,000 persons from 1998 to 2013 – a 6.5% increase for each year.

The study did not explore the causes behind the age-related trends but Dr. Akinboro suggested it may be because of fragmentation of adult SCD care and age- and pain-related medical comorbidities.

The researchers reported having no relevant financial disclosures.

SOURCE: Akinboro OA et al. ASH 2018, Abstract 315.

Recommended Reading

In Ghana, SCD research is meeting patients on home turf
MDedge Family Medicine
Integrated pain program reduced LOS for sickle cell patients
MDedge Family Medicine
Crizanlizumab relieves sickle cell crises across subgroups
MDedge Family Medicine
FDA approves DNA-based blood type test
MDedge Family Medicine
Few clinical outcomes convincingly linked to sickle cell trait
MDedge Family Medicine
Sickle cell disease gene therapy seen advancing
MDedge Family Medicine
Primary care needs pile up for sickle cell patients
MDedge Family Medicine
Researchers seek more sickle cell drug research
MDedge Family Medicine
Daily hydroxyurea effective, safe for African children
MDedge Family Medicine
New treatments promise sickle cell “cure” for all ages
MDedge Family Medicine

Related Articles